XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company’s lead product candidate, gevokizumab, is a proprietary potent, fully humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta. The Company initiated three Phase III clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis. It is also are conducting a trial of gevokizumab in pyoderma gangrenosum (PG), a rare ulcerative skin disease. It also has an active gevokizumab Proof-of-Concept (POC) development program to identify indications for pivotal development. XOMA 3AB is a multi-antibody product designed to neutralize the most potent of the botulinum toxins, Type A, which causes paralysis and is a bioterrorism threat.